Invasive Candida auris infections in Kuwait hospitals: epidemiology, antifungal treatment and outcome
Candida auris is a recently recognized yeast pathogen, which has attracted worldwide attention due to its multidrug-resistant nature and associated high mortality rates. Its persistence in hospital environment and propensity of nosocomial transmission underscores the need of continuous monitoring to prevent outbreaks. Since the first case of C. auris candidemia in May, 2014, we have identified 17 additional invasive cases, which are described here.
Identity of 17 isolates originating from proven or possible cases of invasive C. auris infection and identified as Candida haemulonii by Vitek 2 yeast identification system was confirmed by PCR-sequencing of rDNA. Information about risk factors, treatment and outcomes were retrospectively retrieved from case files. Antifungal susceptibility testing was performed by Etest.
Thirteen cases of candidemia and 4 cases of other invasive infections were detected in 6 hospitals across Kuwait. Major risk factors included adult patients with cancer, diabetes, gastrointestinal/liver diseases and extended (> 25 days) hospital stay. All isolates were resistant to fluconazole. Additionally, 5 and 4 isolates were also resistant to voriconazole and amphotericin B, respectively. Despite antifungal treatment, 9 of 15 patients died. Most patients (n = 12) were hospitalized in 2 hospitals that are in close proximity, whereas 5 other patients were from 3 hospitals that are situated > 10 km apart.
Occurrence of successive cases of invasive C. auris infections with resulting mortality in nine patients suggests persistence of this multidrug-resistant yeast in major hospitals in Kuwait. Early detection by continuous surveillance and enforcement of infection control measures are recommended.
KeywordsCandida auris Invasive infections Epidemiology Antifungal susceptibility Kuwait
Authors are thankful to Soumya Varghese, Sandhya Vayalil and Omar Musallam for excellent technical support.
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
- 14.Arendrup MC, Prakash A, Meletiadis J, Sharma C, Chowdhary A. Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values. Antimicrob Agents Chemother. 2017;61:pii: e00485-17.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Centers for Disease Control and prevention (CDC). Recommendations for identification of Candida auris. https://www.cdc.gov/fungal/diseases/candidiasis/recommendations.html. 2017. Accessed 30 Oct 2017
- 17.Kohlenberg A, Struelens MJ, Monnet DL, Plachouras D, The Candida auris Survey Collaborative Group. Candida auris: epidemiological situation, laboratory capacity and preparedness in European Union and European Economic Area countries, 2013 to 2017. Euro Surveill. 2018;23.Google Scholar
- 23.Ruiz-Gaitan A, Moret AM, Tasias-Pitarch M, Aleixandre-Lopez AI, Martínez-Morel H, Calabuig E, Salavert-Lletí M, Ramírez P, López-Hontangas JL, Hagen F, Meis JF, Mollar-Maseres J, Pemán J. An outbreak due to Candida auris with prolonged colonization and candidemia in a tertiary care European hospital. Mycoses. 2018. https://doi.org/10.1111/myc.12781.PubMedGoogle Scholar
- 25.Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CL. J Clin Microbiol. 2015;53:1823–30.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Prakash A, Sharma C, Singh A, Kumar Singh P, Kumar A, Hagen F, et al. Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism. Clin Microbiol Infect. 2016;22:277.e1–277.e9.CrossRefGoogle Scholar
- 36.Okinda N, Kagotho E, Castanheira M, Njuguna A, Omuse G, Makau P, et al. Candidemia at a referral hospital in sub-Saharan Africa: emergence of Candida auris as a major pathogen. In: European conference on clinical microbiology and infectious: Barcelona; May 10–13 2014.Google Scholar
- 37.Larkin E, Hager C, Chandra J, Mukherjee PK, Retuerto M, Salem I, et al. The Emerging Candida auris: characterization of growth phenotype, virulence factors, antifungal activity, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. Antimicrob Agents Chemother. 2017; 61:AAC.02396-16.CrossRefGoogle Scholar